Characterization of a novel MEF2D-BCL9 fusion positive acute lymphoblastic leukemia cell line WXS
A novel in-house-made pediatric MEF2D-BCL9 fusion positive acute lymphoblastic leukemia cell line was characterized
- 28/11/2022
- 3 samples
- DAC: EGAC00001001864
- Technology: Illumina NovaSeq 6000
DUO:0000007 version: 2021-02-23
disease specific research
This data use permission indicates that use is allowed provided it is related to the specified disease.
ModifiersMONDO_0006517
Data Access Agreement of data controlled by the Data Access Commitee of the Princess Maxima Center for Pediatric Oncology
The Princess Maxima Center for pediatric oncology default access policy to enable re-production of research and re-use of data for scientific purposes. Please contact the DAC (EGAC00001001864) for the most up to date policies.
Studies are experimental investigations of a particular phenomenon, e.g., case-control studies on a particular trait or cancer research projects reporting matching cancer normal genomes from patients.
| Study ID | Study Title | Study Type |
|---|---|---|
| EGAS00001006800 | Exome Sequencing | |
| EGAS00001006801 | Other |
- Changed sample subject id
- Changed sample subject id
- Dataset Released
